SellebjergFBlinkenbergMSorensenPS. Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis. CNS Drugs2020; 34(3): 269–280.
2.
SellebjergFWeberMS. Targeting B cells in multiple sclerosis. Curr Opin Neurol2021; 34(3): 295–302.
3.
KleinCLammensASchaferW, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. Mabs2013; 5(1): 22–33.
4.
EllwardtEEllwardtLBittnerS, et al. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurol Neuroimmunol Neuroinflamm2018; 5(4): e463.
5.
DunnNJutoARynerM, et al. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Mult Scler2018; 24(9): 1224–1233.
6.
AbbadessaGMieleGCavallaP, et al. CD19 cell count at baseline predicts B cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab. Int J Environ Res Public Health2021; 18(15): 8163.
7.
HauserSLBar-OrACohenJA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med2020; 383(6): 546–557.
8.
LunaGAlpingPBurmanJ, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol2020; 77(2): 184–191.
9.
Von EssenMHolm HansenRHøjgaardC, et al. Ofatumumab modulates inflammatory T cell responses and migratory potential in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2022 [In press].
10.
RoodselaarJZhouYLeppertD, et al. Anti-CD20 disrupts meningeal B-cell aggregates in a model of secondary progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2021; 8(3): 975.
